- Home
- PLAB vs ETNB Comparison
PLAB vs ETNB Comparison
Compare PLAB & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLAB
- ETNB
- Stock Information
- Founded
- PLAB 1969
- ETNB 2018
- Country
- PLAB United States
- ETNB United States
- Employees
- PLAB N/A
- ETNB N/A
- Industry
- PLAB Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- PLAB Technology
- ETNB Health Care
- Exchange
- PLAB Nasdaq
- ETNB Nasdaq
- Market Cap
- PLAB 1.4B
- ETNB 1.2B
- IPO Year
- PLAB 1987
- ETNB 2019
- Fundamental
- Price
- PLAB $20.60
- ETNB $8.08
- Analyst Decision
- PLAB Strong Buy
- ETNB Strong Buy
- Analyst Count
- PLAB 1
- ETNB 10
- Target Price
- PLAB $35.00
- ETNB $27.56
- AVG Volume (30 Days)
- PLAB 730.0K
- ETNB 2.1M
- Earning Date
- PLAB 05-21-2025
- ETNB 05-08-2025
- Dividend Yield
- PLAB N/A
- ETNB N/A
- EPS Growth
- PLAB 5.99
- ETNB N/A
- EPS
- PLAB 2.35
- ETNB N/A
- Revenue
- PLAB $862,750,000.00
- ETNB N/A
- Revenue This Year
- PLAB $2.84
- ETNB N/A
- Revenue Next Year
- PLAB $7.54
- ETNB N/A
- P/E Ratio
- PLAB $8.77
- ETNB N/A
- Revenue Growth
- PLAB N/A
- ETNB N/A
- 52 Week Low
- PLAB $19.61
- ETNB $5.99
- 52 Week High
- PLAB $31.60
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- PLAB 40.50
- ETNB 44.60
- Support Level
- PLAB $20.63
- ETNB $7.66
- Resistance Level
- PLAB $21.80
- ETNB $9.32
- Average True Range (ATR)
- PLAB 0.55
- ETNB 0.77
- MACD
- PLAB 0.06
- ETNB 0.02
- Stochastic Oscillator
- PLAB 11.81
- ETNB 49.22
About PLAB Photronics Inc.
Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue worldwide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).